What the FDA labels say about taking them together
Candesartan/hydrochlorothiazide and cyclophosphamide
Candesartan/hydrochlorothiazide's FDA label of December 22, 2025 names cyclophosphamide in its drug interactions section; cyclophosphamide's label does not name candesartan/hydrochlorothiazide itself but warns about its class (ARBs (angiotensin II receptor blockers), Thiazide diuretics). The candesartan/hydrochlorothiazide label: “Cytotoxic products – Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.”
Check it at the source: the candesartan/hydrochlorothiazide FDA label on DailyMed (effective December 22, 2025, ANI Pharmaceuticals, Inc.); the cyclophosphamide FDA label on DailyMed (effective January 19, 2026, Amneal Pharmaceuticals LLC).
What does the candesartan/hydrochlorothiazide label say about cyclophosphamide?
Candesartan/hydrochlorothiazide label, drug interactionsCytotoxic products – Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
Source: FDA drug label (Candesartan Cilexetil and Hydrochlorothiazide), NDA021093 (Ani Pharms), as published by ANI Pharmaceuticals, Inc., effective December 22, 2025 (SPL set bd8d318d-167a-4b26-935d-265dde3193de), via openFDA; the full label on DailyMed
What does the cyclophosphamide label say about candesartan/hydrochlorothiazide?
Cyclophosphamide's label does not name candesartan/hydrochlorothiazide itself; it warns about its class (ARBs (angiotensin II receptor blockers), Thiazide diuretics):
Cyclophosphamide label, drug interactionsIncreased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity ● Anthracyclines ● Cytarabine ● Pentostatin ● Radiation therapy of the cardiac region ● Trastuzumab Increased pulmonary toxicity ● Amiodarone ● G-CSF, GM-CSF (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor) Increased nephrotoxicity ● Amphotericin B ●
Cyclophosphamide label, drug interactionsThiazide diuretics Zidovudine Increased cardiotoxicity Anthracyclines Cytarabine Pentostatin Radiation therapy of the cardiac region Trastuzumab Increased pulmonary toxicity Amiodarone G-CSF, GM-CSF (granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor) Increased nephrotoxicity
Source: FDA drug label (Cyclophosphamide), Amneal Pharmaceuticals LLC, effective January 19, 2026 (SPL set 520bfe39-dfd5-4a20-9a37-80078afded0d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Candesartan/hydrochlorothiazide | Cyclophosphamide | |
|---|---|---|
| Labeled for | High blood pressure | Leukemia, lymphoma and myeloma |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.954 per tablet 16-12.5 mg tablet | $1.67 per capsule 50 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once